NiKang Therapeutics is a technology company.
NiKang Therapeutics has raised $250.0M across 2 funding rounds.
NiKang Therapeutics has raised $250.0M in total across 2 funding rounds.
NiKang Therapeutics has raised $250.0M in total across 2 funding rounds.
NiKang Therapeutics's investors include RTW Investments.
NiKang Therapeutics is a clinical-stage biotechnology company founded in 2017, specializing in the discovery and development of innovative small molecule drugs for oncology, targeting difficult-to-drug proteins like HIF2α, CDK2, and KRAS to address unmet needs in cancer treatment.[1][2] The company employs structure-based drug design and disease biology insights to advance precision medicines, with three candidates—against SHP2, HIF2α, and CDK2—already in first-in-human clinical testing; recent milestones include completing dosing of the first cohort in Phase 1 studies for NKT5097 (CDK2/4 dual degrader) in September 2025 and NKT3964 (CDK2 degrader) in March 2025.[1] NiKang serves cancer patients with serious unmet needs, solving challenges in modulating hard-to-target pathways through highly potent, selective, orally bioavailable degraders, demonstrating strong growth momentum via rapid pipeline progression from discovery to clinic in under a decade.[1][2][3]
NiKang Therapeutics was established in 2017 by co-founders Zhenhai Gao (CEO, President, and Director, with a background in chemistry) and Yan Lou (Chief Scientific Officer, a biologist), driven by a shared vision to develop new medicines for patients with serious unmet medical needs, particularly in oncology.[1][2][4] The idea emerged from their expertise in biology and chemistry, leading to a focus on structure-based drug design informed by target structural biology and disease pathways; the company name combines "Nike" (Greek goddess of victory, implying speed and strength) and "Kang" (Chinese for good health), reflecting their mission to conquer cancer.[2] Early traction came swiftly, as NiKang advanced three small molecule drugs into clinical testing since inception, marking pivotal moments in challenging conventional oncology drug discovery.[1][2]
NiKang rides the wave of targeted protein degradation and precision oncology, where degraders like PROTACs and molecular glues offer advantages over inhibitors by fully eliminating disease-causing proteins, addressing resistance in cancers driven by HIF2α, CDK2, and KRAS—targets central to renal cell carcinoma, breast cancer, and beyond.[1] Timing is ideal amid surging investment in small molecule modalities post-2020s breakthroughs (e.g., approved degraders), with market forces like aging populations, rising cancer incidence, and demand for oral therapies favoring NiKang's rapid clinical progress.[1][3] The company influences the biotech ecosystem by validating structure-based design for "undruggable" targets, inspiring peers and attracting partners like HBM Partners, while contributing to a shift toward pathway-selective oncology drugs that improve patient outcomes.[2][3][4]
NiKang's near-term path involves advancing Phase 1 data readouts for NKT5097 and NKT3964, potentially expanding to combination trials or new indications, with broader pipeline growth in KRAS and autoimmune applications amid degraders' rising dominance.[1][4] Trends like AI-enhanced structure prediction and multi-target degraders will accelerate their momentum, evolving NiKang from clinical-stage challenger to potential oncology leader through partnerships or IPO, as seen in comparable biotechs.[3][4] This positions them to deliver on their victory-over-cancer ethos, transforming unmet needs into healthier lives.
NiKang Therapeutics has raised $250.0M across 2 funding rounds. Most recently, it raised $200.0M Series C in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $200.0M Series C | RTW Investments | |
| Sep 1, 2020 | $50.0M Series B | RTW Investments |